Medifast vs Omada Health
MED and OMDA side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MED and OMDA compare
Omada Health is the larger company, worth 6.0 times as much as Medifast ($877M against $145M).
Omada Health grew revenue faster over the last twelve months (43.3% versus −30.3% for Medifast).
Omada Health keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with −13.6% at Medifast.
Omada Health scores higher on the StockData Score (13 against 10 for Medifast), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MED | OMDA |
|---|---|---|
| Size and price | ||
| Market cap | $145M | $877M |
| Share price | $12.97 | $14.33 |
| Change, 1 year | 11.5% | −33.2% |
| Change, 5 years | −94.1% | – |
| Beta (5Y) | 0.71 | 2.29 |
| Employees | 380 | 916 |
| StockData Score | ||
| Total score | 10 | 13 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 | 3 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 2.6× |
| P/B | 0.8× (better) | 3.2× |
| EV/EBITDA | – | 48.5× |
| P/FCF | – | 31.2× |
| FCF yield | −2.7% | 3.2% (better) |
| Fair value | $35.80 | $9.16 |
| Margin of safety | 63.8% (better) | −56.4% |
| Growth | ||
| Revenue growth (TTM) | −30.3% | 43.3% (better) |
| Revenue growth, 5Y average | −16.2% | – |
| Net income growth (TTM) | −16573% | – |
| EPS growth (TTM) | −37000% | – |
| Profitability | ||
| Gross margin | 69.2% | 70.7% (better) |
| Operating margin | −11.6% | 2.1% (better) |
| Net margin | −13.6% | 4.2% (better) |
| FCF margin | −1.3% | 8.5% (better) |
| Return on equity | −20.7% | 5.7% (better) |
| Return on invested capital | −110% | 28.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 22.4× |
| Current ratio | 4.82 (better) | 4.18 |
| Altman Z-score | 3.83 | 7.03 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 73.9% | 85.9% |
| Held by insiders | 12.3% | 5.4% |
| Insider net buying, 12 months | $1.5M (better) | −$14.6M |
| Short interest, % of float | 13.2% | 15.8% |
Go deeper
- MED stock overview
- MED income statement
- MED valuation and score
- OMDA stock overview
- OMDA income statement
- OMDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.